Lexaria is technology for improved delivery of bioactive compounds.

Lexaria Bioscience Corp. | Medical Cannabinoid Research | Purple Logo CSE:LXX; OTCQX:LXRP

Welcome to Lexaria Bioscience Corp.

Lexaria Bioscience Corp’s ( OTCQX:LXRP / CSE:LXX;) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing.

The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 – 2 hours to 15 – 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.

Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles, and oral products and to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.

Learn More

Introducing Lexaria and DehydraTECH Technology

About DehydraTECH

Lexaria’s patented technology, DehydraTECH™ delivers these important benefits:

Masks taste/odor

Eliminates the strong tastes/odors of lipophilic compounds, without the need for unwanted sugar or sweeteners

Reduces time of onset

Effects are felt within 15-20 min vs. 60-120 min.

Avoids first-pass liver metabolism

Initial testing indirectly evidences DehydraTECH may deliver ingested molecules through the lymphatic system instead of being subject to immediate “first pass” liver exposure, potentially mitigating unwanted side effects and reducing liver biotransformation.

Increases bio-absorption

Bio-absorption increases up to 3 – 10X, to equate or exceed that of other routes of administration like inhalational delivery.

Lexaria’s disruptive new technology DehydraTECH can be licensed to improve existing drug delivery through orally-ingested products; or create revolutionary new ones.

DehydraTECH Commercial Applications

Lexaria’s DehydraTECH™ is designed specifically for formulating and delivering lipophilic (i.e. fat-soluble) drug payloads. It is patented or patent-pending for use with a broad range of bioactive molecules, including but not limited to:

Nicotine

Pharmaceuticals

Hemp-Derived Compounds

The people behind the science

Interview with CEO Chris Bunka of Lexaria BioScience

Learn More

The technology behind the products

Lexaria’s DehydraTECH

Learn More

Latest News

Upcoming Events

View All Events